Abstract. To clarify how Alzheimer disease pathology develops in the brains of nondemented subjects, we examined the interrelations among the amounts and morphology of A␤ deposition, neurofibrillary pathology, and apolipoprotein E (ApoE) genotype in the frontal association cortex of 101 autopsy brains from patients aged between 40 to 83. Senile plaque density correlated well with the logarithmic data of insoluble A␤ measured by enzyme immunoassay (EIA). The amounts of A␤42-EIA increased dramatically in the late preclinical stage, whereas the A␤42ϩ plaque density increased in the early preclinical stage. Neurofibrillary pathology appeared only in the areas with severe A␤ deposition and in subjects aged over 70. The ApoE 4 allele enhanced the A␤ deposition in presenile subjects. Plaque-associated glial A␤ was prominent in subjects with mild to moderate A␤ deposition. The morphology of cerebral A␤ deposition changed from diffuse plaques with small amounts of A␤ in each plaque in the early preclinical stage to primitive/neuritic plaques with larger amounts of A␤ in each plaque in the late preclinical stage. Our findings suggest that the prevention of A␤ deposition in the late preclinical stage can be a rational therapeutic target, especially in elderly people with ApoE 4 allele.
INTRODUCTION
The deposition of amyloid ␤ protein (A␤) as senile plaques and cerebral amyloid angiopathy (CAA) is one of the neuropathological hallmarks of Alzheimer disease (AD). A␤ is a hydrophobic self-aggregating peptide consisting of 40-42 residues (1), and is derived from a larger membrane-bound protein, amyloid ␤ protein precursor (APP) (2) . Analyses of the A␤ peptide sequence showed some heterogeneity in the C-terminal end of A␤; the longer species, A␤x-42 (A␤42), and the shorter species, A␤x-40 (A␤40). Immunohistochemical studies have shown that A␤42 is present as a major species in the initial stage of plaque formation (3, 4) .
Recently, longitudinal studies on nondemented elderly people revealed the presence of an intermediate stage named mild cognitive impairment (MCI), which is between no cognitive impairment (NCI) and mild AD stages (5, 6) . MCI refers to individuals who have memory impairment greater than expected for their age; yet general cognitive function is preserved, and therefore, MCI subjects do not meet the criteria for AD (6) . NCI nearly corresponds to the Clinical Dementia Rating Scale (CDR) of 0, MCI to CDR 0.5, and mild AD to CDR 1 or 2 (7). This means that preclinical or nondemented stage can be divided into 2 stages: early preclinical (NCI/CDR 0) and late preclinical (MCI/CDR 0.5). When MCI subjects were followed longitudinally, they converted to clinically probable AD at a rate of 10%-15% per year, which was 10 times more frequently than NCI subjects converted to AD (1%-2% per year) (6) . Finally, a high percentage of patients with MCI developed into early AD (5) . Neuropathological studies on MCI subjects revealed that they had an intermediate value of mean ␤-amyloid load between that in NCI and AD (7) (8) (9) (10) (11) . In the association cortex, MCI subjects had no or few neurofibrillary tangles (NFTs) and corresponded to Braak stage II or III (7, 12) , suggesting that MCI is an intermediate stage between NCI and AD.
In the current study on nondemented subjects, we evaluated the amounts of A␤ deposition by both immunohistochemistry (IHC) and 2-sites enzyme immunoassay (EIA), examined the neurofibrillary pathology by phosphorylated tau-IHC and ApoE genotype, and analyzed the relation between these markers. Neuro-psychological testing was not done. We also discussed the time sequence of pathological legions in the frontal association cortex in the preclinical stage of AD.
The 4 allele of apolipoprotein E (ApoE) has been established as a risk factor of AD by promoting cerebral A␤ deposition (13) (14) (15) . A recent immunohistochemical study reported that ApoE 4 promoted the early deposition of A␤42 in the nondemented elderly people, whereas ApoE 4 was associated with greater A␤40 deposition in end-stage of AD (16) . We were also interested as to whether ApoE 4 gene is related to early A␤ deposition.
MATERIALS AND METHODS
We collected autopsied brains from 101 patients who died in the Gunma Cancer Center due to malignant neoplasms. None of the patients showed any signs of dementia in their daily life, although no special examination for detecting mental decline was carried out. The 101 subjects died between ages 40 and 83 yr (mean 65.1 yr) and were divided into 4 groups according to their age (Table 1) . Of the 101 subjects, brain radiation therapy had been administrated in 15 cases (8-66 Gy). History of cerebral infarction was found in 4 subjects, but none had a known history of head trauma. We took approximately 100 g tissue block from the frontal association cortex (Brodmann 9, 10 and 11) of each subject, and stored it at Ϫ80ЊC before use. Most samples were taken within 2-4 h postmortem. Frozen brain samples from 2 AD patients, aged 83 and 86, were added as a positive control.
For the comparison between immunohistochemistry and EIA measurement of A␤, frozen brain samples from area 9 or 10 (approximately 3 cm 3 ) were cut into 2 pieces. One third was used for the EIA measurement of A␤. Small brain tissue (120 mg) was homogenized in 4 volumes of Tris-saline using Teflon/ grass homogenizer and centrifuged at 100,000 ϫ g for 60 min. The washed pellet was re-suspended in 50 volumes of 70% formic acid and centrifuged. The formic acid-soluble fraction, which was neutralized with NaOH and Trizma base, was subjected to 2-site EIA, using BNT77 (monoclonal, A␤11-28) as the capture antibody and BA27 (monoclonal, A␤40 end-specific) or BC05 (monoclonal, A␤42 end-specific) as the horseradish peroxidase-tagged detection antibody (17) . The remaining two thirds was fixed overnight in 4% formaldehyde solution at 4ЊC and embedded in paraffin. Serial sections, 3 m-thick, were immunostained with the following antibodies: 1) MBC42, A␤42 end-specific monoclonal (1:100, culture sup) (18); 2) MBC40, A␤40 end-specific monoclonal (1:20, culture sup) (18); 3) G42, pan-A␤, rabbit (1:1,000) (18); 4) PS199, recognizing phosphorylated Ser199 of tau, rabbit (1:500, a gift from Dr. Ishiguro) (19) ; and 5) anti-normal human tau, rabbit (1:500) (20) . Immunoreaction was visualized using a Vectastain ABC Elite kit (Vector, Burlingame, CA) and diaminobenzidine and H 2 O 2 solution. As controls, A␤ antibodies were preabsorbed using corresponding synthetic ␤ peptides (Bachem, Torrance, CA), and we confirmed the absence of immunoreaction in the adjacent section. After confirming the positive staining by comparing with the control and G42 stains, the density of senile plaques was measured by observing an entire tissue section stained by MBC42 or MBC40 and expressed semi-quantitatively: ϩ/Ϫ only 1 or 2 small areas in an entire tissue section show 1 or 2 senile plaques (focal presence); ϩ, senile plaques appear in several areas in an entire tissue section but mean density (average of 20 randomly selected areas) is less than 1/mm 2 ; ϩϩ, senile plaques appear in the some cortical layers and the plaque density is between 1 and 10/mm 2 ; ϩϩϩ, senile plaques appear in most cortical layers and plaque density is more than 10/mm 2 . The interrelation between morphology and amounts of cerebral A␤ deposition, neurofibrillary pathology, and ApoE genotype was statistically analyzed in 101 subjects using t-test, Kruskal-Wallis test and chi-square test.
RESULTS

Comparison of A␤-IHC and A␤-EIA
Sensitivity: A␤42-IHC using MBC 42 was quite sensitive and labeled all A␤ deposition detected by pan-A␤ antibody G42. From 101 patients, 44 subjects (43%) were negative for both A␤42-IHC (neither plaques nor CAA) and A␤42-EIA (Ͻ12 pmol/g) (Fig. 1a) . In 11 of the 55 A␤42-EIAnegative subjects, we found 1 or 2 senile plaques and CAA per entire tissue section (A␤42-IHC ϩ/Ϫ) (Figs. 1a, 2i ). Alternately, in 5 of 50 A␤42-IHC-negative subjects, we found 14 to 39 pmol/g of A␤ by EIA (Fig. 1a) . We consistently found A␤ deposition by IHC when EIA data were higher than 41 pmol/g. Both A␤42-IHC and A␤42-EIA were equally sensitive. A␤40-IHC showed lower numbers of plaques than A␤42-IHC did (Fig. 1b) . However, senile plaques were faintly or weakly positive for A␤40 together with moderate A␤42 labeling when plaque density was quite low (Figs. 2g-j, 3). Values of A␤40-EIA were always lower than those of A␤42-EIA, and A␤40-EIA was less sensitive than A␤40-IHC. Correlation: A␤42-IHC correlated well with the logarithmic value of A␤42-EIA (Fig. 1a) . When A␤42-EIA values were between 12 and 99, A␤42-IHC frequently showed focal A␤ deposition as a form of diffuse plaques (Fig. 2g) . When A␤42-EIA data were between 100 and 999, small numbers of senile plaques (mostly diffuse plaques) frequently appeared in ϫ4 visual fields (Fig. 2e) . Between 1,000 and 9,999 we consistently found considerable numbers of senile plaques in the cortical layers III and IV (Fig. 2c) . Cored plaques were found in some subjects. In samples over 10,000 with A␤42-EIA, senile plaques appeared in the entire cortical layers as seen in AD, but plaque density seen by A␤40-IHC was less than that in AD (Fig. 1a, b) . Correlation between A␤40-HIC and A␤40-EIA (R 2 ϭ 0.53) was significant, but weaker than that between A␤42-HIC and A␤42-EIA (R 2 ϭ 0.85) (Fig. 1) . In 71 A␤40-EIA-negative (less than 12 pmol/g) subjects, 14 had focal A␤ deposition (A␤40-IHC ϩ/Ϫ Fig. 2h , j) and 3 had some disseminated A␤ deposition (A␤40-HIC ϩ; Fig. 2f ). A␤40-IHC varied from negative (Ϫ) to moderate amounts (2ϩ) in 23 subjects whose A␤40-EIA data were between 12 and 99. A␤40-EIA tended to be positive when the A␤42-EIA value was over 100 pmol/g. CAA was found in 16 subjects by A␤42-IHC and 14 of them were also positive for A␤40-IHC (Fig. 4) . Five of the 16 subjects had CAA without senile plaques.
Interrelation between Aging, A␤ Deposition and Neurofibrillary Pathology
As shown in Table 1 , cerebral A␤ deposition was found in all age groups by A␤42-IHC, and the prevalence of A␤ deposition (percentage of subjects with A␤ deposition) increased with aging. When male and females were compared, middle-aged females tended to show a higher prevalence, although the number of the subjects was too small for statistical analysis (Table 1) . We found phosphorylated tau-IHC-positive neurons (p-tauϩ neurons) in 7 of 101 subjects. All of them were aged over 70 yr and the mean age (77.7 yr) was significantly higher (p Ͻ 0.05) than that of the subjects without p-tauϩ neurons (64.7 yr). As shown in Figure 1 , p-tauϩ neurons were not found in the subjects with small amounts of A␤ deposition (A␤42-IHC ϩ/Ϫ or 1ϩ subjects), whereas 3 of the 13 A␤42-IHC 2ϩ subjects and all 4 A␤42-IHC 3ϩ subjects showed p-tauϩ neurons. Most of these 7 subjects also had high A␤42-EIA values (mean 8,628 pmol/g). In 9 subjects with abundant A␤42 deposition (A␤42-EIA, Ͼ4,000 pmol/g), 6 had p-tauϩ neurons, whereas only 1 subject (A␤42-EIA, 683 pmol/g) had ptauϩ neurons out of 92 with moderate to no A␤42 deposition (A␤42-EIA Ͻ4,000 pmol/g). Values of A␤40-EIA varied from 35 to 1,240 pmol/g in the 7 subjects with p-tauϩ neurons (Fig. 1b) . Tau-IHC showed an accumulation of degenerating neurites in primitive/neuritic plaques in 3 subjects (A␤42-EIA, 4,500, 6,164, and 28,700 pmol/g; Fig. 6a, b) . The density of p-tauϩ neurons in nondemented subjects was much lower than that seen in AD (Fig. 6c) . In 6 of 7 subjects, density of the p-tauϩ neurons was quite low (less than 0.1/mm 2 ), and 0.3/mm 2 in 1 subject with the highest A␤42-EIA value. The shape of the tau-positive neurites was straight, but not tortuous like the neuropil threads/curly fibers in AD (Fig. 6c) .
Relationship between ApoE Genotype and A␤ Deposition
In 101 subjects, 21 had 1 or 2 copies of ApoE 4 allele (4ϩ group). The 4ϩ group showed significantly higher (nearly 2 times) prevalence of A␤ deposition than the 4-group (2ϫ2, 2 ϭ 9.2, p Ͻ 0.05), whereas mean age was not significantly different between the 2 groups (Table 1) , and CAA was also found 2 times more frequently in the 4ϩ group, suggesting that the 4 allele accelerates both vascular amyloid deposition and senile plaque formation. When analysis was done in 40 presenile subjects (younger than 65), the 4ϩ group (5/9, 55.5%) showed a significantly higher prevalence of A␤ deposition (2ϫ2, 2 ϭ 4.2, p Ͻ 0.05) than the 4Ϫ group (9/31, 29.0%). The prevalence of A␤40-EIA-positive subjects was also increased nearly 2 times in the 4ϩ group (Table 1) . The relation between A␤42-EIA levels and the age of the subjects is shown in Figure 6 . Most subjects in the 4ϩ group (closed circles) were above the base line (12 pmol/ g), whereas more than half subjects in the 4Ϫ group (open circles) were on the base line (A␤42-EIA-negative). In the 32 subjects with A␤42-EIA level of more than 100 pmol/g, 14 subjects (44%) had 1 or 2 ApoE 4 alleles.
Intraglial A␤-Positive Granules
In this study, we frequently found intraglial A␤-positive granules that usually appeared around weakly labeled diffuse plaques. The plaque area tended to be positive for both MBC42 and MBC40 (Fig. 3) , although 10 of 23 A␤-positive glia-bearing subjects were A␤40-EIA-negative. The A␤-positive glia was prominent in subjects with mild (ϩ) to moderate (2ϩ) A␤ deposition, but not in subjects with a high density (3ϩ) of senile plaques (Fig.  7) . ApoE 4 allele did not affect the presence of glial A␤-granules.
DISCUSSION
We used the term ''p-tauϩ neurons'' instead of NFTs, because in the nondemented subjects the p-tauϩ neurons consisted of pretangles and early tangles, most of which might not be detected by Bodian stain (21) . In the current study, the presence of the p-tauϩ neurons was limited to elderly subjects (over 70 yr of age) with large amounts 734 ID 19 (a, b) was 75 yr old, and the ApoE genotype was 3/3. A␤42-EIA was 28,700, and A␤40-EIA was 1,280. In 2 subjects, ID 47 (g, h) and ID 9 (i, j), senile plaque, which was MBC42-positive (i) and also MBC40 weakly positive, was incidentally found only in 1 area of the entire tissue section. ϫ26.
of A␤ deposition, whereas both A␤42-EIA and A␤42-IHC were positive in subjects from age 40 upwards. Furthermore, no one showed neurofibrillary pathology without A␤ deposition. From these findings, we suggest that massive A␤ deposition precedes the presence of p-tauϩ neurons in the frontal association cortex, and that the time lag between the onset of A␤42 deposition and NFT formation is 10 to 20 yr in the frontal association cortex. Although NFT formation preceded the A␤ deposition in hippocampal CA1 and locus ceruleus (22) , NFT formation in the frontal association cortex seemed to follow moderate to massive A␤ deposition. Aggregated A␤ may activate the GSK-3␤ (23), which is an important tau kinase and present in NFTs (19) . Actually, massive amyloid deposition in the blood vessel wall was reported to promote accumulation of tau-immunoreactive cell processes around the vessels (perivascular neurofibrillary pathology) (24) . In the frontal association cortex, the presence of numerous senile plaques with no or few NFTs was a characteristic feature of MCI stage, and that of abundant plaques together with disseminated NFTs was a feature of AD (7, 12, 25) .
In the present study, A␤ deposition began in the fifth decade as shown in our previous study on another 123 middle-aged subjects with malignant neoplasms (26) . The large-scale study of Braak et al (27) also showed an agedependent increase of A␤ deposition from 40 yr of age. In the current study, the prevalence of A␤ deposition was much higher than that expected from the findings of nondemented subjects (17, 27) . The ApoE 4 allele frequency of the current subjects (0.114) were nearly 2 times higher than that of Japanese control subjects (0.05-0.06) (28, 29) . Furthermore, we used briefly fixed brain tissues for IHC that were once frozen and immunostained with a highly sensitive antibody, MBC42. Under careful observation at a high-power field, we could detect solitary plaques showing faint A␤ labeling. Therefore, the sensitivity of A␤42-IHC was similar to A␤42-EIA, which contradicts the findings in a previous study where IHC detected senile plaques in the subjects over 100 pmol/g of A␤42-EIA (17) .
In the current EIA study, the amounts of A␤ dramatically increased in the subjects with 2ϩ to 3ϩ A␤42-IHC, agreeing with the findings of a logarithmic increase of A␤ deposition measured by EIA (17) . Cortical senile plaque density was reported to reach nearly maximal in subjects with mild AD (9) . Studies on asymptomatic mutation carriers of the APP and presenilin 1 gene have shown a linear and disease-related decline in most cognitive functions that begins approximately 10 yr before the expected clinical onset of AD (5). The Baltimore Longitudinal Study of Aging showed that the estimated median time of conversion from MCI to AD was 4.4 yr (30) . From these findings, we speculated the time sequence of legions in a representative subject as shown in Figure 8 . The plaque density may increase in the early preclinical (NCI) stage and may reach plateau in the mild AD stage. In contrast, the real amounts of insoluble A␤, measured by EIA, may steeply increase in the late preclinical (MCI) stage (Fig. 8) . This means that the amount of A␤ in each plaque increases in the late preclinical stage in parallel with the maturation of the plaque from diffuse to primitive/neuritic plaques, although the increased plaque density is another factor. Recently, we reported the ultrastructural localization of A␤ in diffuse plaques by postembedding gold labeling (31) . In the early stage of diffuse plaques, A␤ appeared exclusively as a membrane-bound form on cell surface plasma membrane and no apparent amyloid fibrils were found. In the advanced stage of diffuse plaques, small amounts of amyloid fibrils appeared between cell processes. In primitive plaques, bundles of amyloid fibrils appeared much more frequently with degenerating neurites (32) . The amount of A␤ was quite small in diffuse plaques, the predominant form in the early preclinical stage. However, it became quite large in each primitive/neuritic plaque, the density of which increased in the late preclinical stage (Fig. 8) .
In this study, we have shown cerebral A␤ deposition in a subset of nondemented subjects. Neuropathological studies of the subjects in the MCI stage revealed intermediate amounts of A␤ deposition between those in NCI and AD stages as measured by IHC (8-10) and EIA (11) .
As stated by Morris et al (8) , these findings suggest that senile plaques may not be a part of ''normal'' aging but instead represent presymptomatic or unrecognized early symptomatic AD, although the presence of senile plaques in the neocortex of apparently nondemented elderly subjects are often accepted as a part of ''normal'' aging. Thus, we speculate that plaque density does not correlate well to the degree of dementia when examined in the AD subjects (33) (34) (35) , but the amounts of A␤, especially those measured by EIA, may correlate with the degree of cognitive impairment in preclinical/mild AD subjects (Fig.  8) (11, (36) (37) (38) (39) . Our findings seem to contradict the findings of Terry et al that synapse loss is the major correlate of cognitive impairment in AD (40) . They analyzed the correlation using 2 groups; 15 mild to severe AD subjects and 9 neuropathologically normal subjects whose brains had no or minimal A␤ deposition (NCI group). They did not examine the correlation in the MCI group, which should further elucidate which is the major correlate of cognitive impairment in the MCI subjects-A␤ deposition or synaptic loss.
Unfortunately, our subjects were not examined neuropsychologically, and therefore, we could not analyze whether subjects with large A␤ deposition were in the MCI stage or not. However, in the nursing records of the subject with the highest A␤ deposition (ID 19, A␤42-EIA 28,700 pmol/g, Fig. 2a) , memory impairment was noted. In the current study, even with high amounts of A␤42, the amounts of A␤40 and degree of neurofibrillary pathology were much less than those seen in the typical AD subjects. In the frontal cortex, NFTs were usually absent in the preclinical stage and NFTs became apparent first in subjects with mild AD (7). In this study, we showed that ApoE 4 genotype was associated with earlier onset of A␤42 deposition, agreeing with the preceding studies showing that an 4 allele predicted an earlier onset of A␤ deposition (16, 29, 41, 42) . In the subjects with considerable A␤ deposition (more than 100 pmol/g of A␤42-EIA), however, about half of them were without an ApoE 4 allele. This 4 allele frequency was similar to that in AD subjects (13, 14) . A recent immunohistochemical study reported that ApoE 4 promoted the earlier deposition of A␤42 in the nondemented elderly people, whereas ApoE 4 was associated with greater A␤40 deposition in end-stage of AD (16) . They suggested that the increased A␤40 in ApoE4-positive AD cases probably was due to the earlier onset of cerebral amyloidogenic processes in their cases, which began with deposition of A␤42. They also hypothesized that the number of diffuse, A␤42-plaques eventually reaches a steady state in advanced AD, where the emergence of new diffuse plaques is in equilibrium with their transformation into A␤40-positive mature plaques and disappearing processes. In another point of view, ApoE isoforms were reported to bind differently to tau (43, 44) and NFT-bearing neurons tended to be ApoE-immunoreactive (45, 46) , and thus ApoE was related to NFT formation. ApoE 4 was associated with denser NFT formation throughout the age span examined (60-100 yr) in the nondemented elderly people, although enhancing effect of 4 on A␤ deposition appeared milder with increasing age (47) . However, the mechanism by which ApoE 4 influences the metabolism of A␤ has yet to be elucidated. In the transgenic mouse model, ApoE knockout caused decreased A␤ deposition in APP Sw -transgenic mice, suggesting that ApoE enhanced the amyloid deposition (48) . Another study, using mice with human ApoE 3/3-or 4/4-knock-in and APP V717F -transgenes, showed that E4 enhanced amyloid fibril formation and neuritic plaques more than E3 (49) . E3 and E4 isoforms differ by 1 amino acid sequence, and therefore the chemical that binds to E4 and changes its 3-dimentional structure to match E3, can be useful in preventing AD in MCI subjects with ApoE 4 allele.
In the brains of nondemented subjects, we have reported the ''disappearing plaques,'' which were diffuse plaques associated with astroglial A␤ granules, and discussed a dynamic balance between plaque formation and destruction (18) . This hypothesis was supported by the immunization study of APP V717F transgenes, in which A␤ immunization prevented or removed cerebral A␤ deposition (50) . In the current study, we found that astroglial A␤ was prominent from the beginning of A␤ deposition, but became scarce in the high A␤ load stage (A␤42-IHC 3ϩ). In the preclinical stage of AD, astroglia may attempt to remove A␤ in diffuse plaques. Diffuse plaques, which were associated with grail A␤-positive granules, tended to be immunoreactive for both A␤40 and 42 antibodies.
In the early preclinical stages, quite small amounts of A␤40 colocalized with A␤42 in disappearing plaques, whereas both the plaque density and amounts of A␤ were too low to be detected by EIA. The presence of disappearing plaques in the preclinical stage suggests that the prevention of A␤ deposition at this stage can be a rational therapeutic target, especially in ApoE 4-bearing elderly people.
